ATR and neoplasm: To investigate whether the adaptive antitumor immunity potentiated by combined ATR inhibition and ablative radiotherapy enhanced systemic immunotherapy responses in vivo, we established a synchronous LLC lung and flank tumor mouse model (Fig. 3D).